Danshensu

• Description:

  Danshensu (Dan shen suan A), an orally active phenolic compound, can induce Nrf2/HO-1 activation and inhibition of NF-κB pathway. Danshensu reduces reactive oxygen species (ROS) production, upregulates antioxidant defense mechanism and inhibits intrinsic apoptotic pathway. Danshensu displays a potent antiviral activity against SARS-CoV-2 with EC50 of 0.97 μM. Danshensu has anti-oxidation, anti-apoptosis, anti-lung inflammatory and has the potential for COVID-19, cardiovascular and cerebrovascular diseases research[1][2][3].

• Product Name Alternative:

  Dan shen suan A; Salvianic acid A

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Apoptosis; Keap1-Nrf2; NF-κB; Reactive Oxygen Species (ROS) ; SARS-CoV

• Type:

  Natural Products

• Related Pathways:

  Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Infection; Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Danshensu.html

• Purity:

  98.59

• Solubility:

  DMSO : < 1 mg/mL|H2O : 5 mg/mL (ultrasonic)

• Smiles:

  OC1=C (C=CC (C[C@H] (C (O) =O) O) =C1) O

• Molecular Formula:

  C9H10O5

• Molecular Weight:

  198.17

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Wei Wang, et al. Danshensu alleviates pseudo-typed SARS-CoV-2 induced mouse acute lung inflammation. Acta Pharmacol Sin. 2022 Apr;43 (4) :771-780. |[2]V Bharath Kumar, et al. Sodium Danshensu Inhibits Oral Cancer Cell Migration and Invasion by Modulating p38 Signaling Pathway. Front Endocrinol (Lausanne) . 2020 Sep 30:11:568436. |[3]Chen Yu, et al. Danshensu attenuates cisplatin-induced nephrotoxicity through activation of Nrf2 pathway and inhibition of NF-κB. Biomed Pharmacother. 2021 Oct:142:111995.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Natural Products

• Clinical Information:

  No Development Reported

• Citation 01:

  Breast Cancer Res Treat. 2024 Dec;208 (3) :657-671.|Cancer Immunol Immunother. 2025 Jun 30;74 (8) :256.|J Tradit Complement Med. 2025 Feb 7;15 (4) :434-445.|Phytomedicine. 2023 May:113:154743.|Eur J Pharmacol. 2025 Feb 1:177296.

• CAS Number:

  76822-21-4